Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIc Trial of Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study

Next Previous
Trial Profile

A Phase IIc Trial of Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Clofazimine (Primary) ; Rifapentine (Primary) ; Ethambutol; Isoniazid; Pyrazinamide; Pyridoxine; Rifampicin
  • Indications Pulmonary tuberculosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CLO-FAST; The CLO-FAST Study

Most Recent Events

  • 14 Nov 2024 The PHOENIx MDR-TB and CLO-FAST studies are sponsored by the NIH's National Institute of Allergy and Infectious Diseases (NIAID, which also funds ACTG) under award numbers UM1 AI068636, UM1 AI107716, and UM1 AI068634.
  • 14 Nov 2024 According to an ACTG media release, CLO-FAST is led by John Metcalfe, M.D., Ph.D., M.P.H., University of California San Francisco; Samuel Pierre, M.D., Les Centres Gheskio, Haiti; and Kimberly Scarsi, Pharm.D., M.S., University of Nebraska Medical Center and study drugs were supplied by the Global Drug Facility. This study is sponsored by the National Institute of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID, which also funds ACTG).
  • 14 Nov 2024 According to an ACTG media release, data from this study was presented in an oral presentation titled "Six Months is a Lot of Time to Lie:" Disclosure and Treatment Preferences Among Participants in a Tuberculosis Therapeutic Trial, at The Union Conference on Lung Health 2024, in Bali, Indonesia.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top